At the time of writing, Tyra Biosciences Inc [TYRA] stock is trading at $11.50, up 7.08%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TYRA shares have gain 5.12% over the last week, with a monthly amount drifted -4.49%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tyra Biosciences Inc [NASDAQ: TYRA] stock has seen the most recent analyst activity on January 07, 2025, when UBS initiated its Buy rating and assigned the stock a price target of $28. Previously, BofA Securities upgraded its rating to Buy on October 18, 2024, and elevated its price target to $31. On August 15, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $33 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $15 on December 15, 2023. Wedbush initiated its recommendation with a Outperform and recommended $27 as its price target on June 30, 2023. Oppenheimer started tracking with a Outperform rating for this stock on February 03, 2023, and assigned it a price target of $17. In a note dated June 23, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $12 on this stock.
For the past year, the stock price of Tyra Biosciences Inc fluctuated between $9.93 and $29.60. Currently, Wall Street analysts expect the stock to reach $31.33 within the next 12 months. Tyra Biosciences Inc [NASDAQ: TYRA] shares were valued at $11.50 at the most recent close of the market. An investor can expect a potential return of 172.43% based on the average TYRA price forecast.
Analyzing the TYRA fundamentals
Gross Profit Margin for this corporation currently stands at 0.3% with Operating Profit Margin at -199.39%, Pretax Profit Margin comes in at -166.81%, and Net Profit Margin reading is -166.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.25 and Total Capital is -0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.70 points at the first support level, and at 9.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.06, and for the 2nd resistance point, it is at 12.62.
Ratios To Look Out For
It is important to note that Tyra Biosciences Inc [NASDAQ:TYRA] has a current ratio of 29.55. In addition, the Quick Ratio stands at 29.55 and the Cash Ratio stands at 8.4.
Transactions by insiders
Recent insider trading involved Kjellson Nina S, Director, that happened on Feb 05 ’25 when 5401.0 shares were sold. Director, Canaan XI, LP completed a deal on Feb 05 ’25 to buy 0.12 million shares. Meanwhile, Director Canaan 2020 Plus Co-Investment bought 0.11 million shares on Feb 05 ’25.
